Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VTYX Ventyx Biosciences, Inc.

Not Yet Opened 12-10 16:00:00 EST

8.69

+0.18

+2.12%

盘后8.31

-0.38-4.40%

19:39 EST

High8.72	Low8.39	Vol836.98K
Open8.50	D1 Closing8.51	Amplitude3.88%
Mkt Cap620.11M	Tradable Cap465.40M	Total Shares71.36M
T/O7.19M	T/O Rate1.56%	Tradable Shares53.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VTYX","market":"US","secType":"STK","nameCN":"Ventyx Biosciences, Inc.","latestPrice":8.69,"timestamp":1765400400000,"preClose":8.51,"halted":0,"volume":836981,"hourTrading":{"tag":"盘后","latestPrice":8.3075,"preClose":8.69,"latestTime":"19:39 EST","volume":16903,"amount":146837.3929,"timestamp":1765413576046},"delay":0,"floatShares":53555855,"shares":71358638,"eps":-1.499056,"marketStatus":"Not Yet Opened","change":0.18,"latestTime":"12-10 16:00:00 EST","open":8.5,"high":8.72,"low":8.39,"amount":7193324.39697,"amplitude":0.038778,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.499056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":0,"adr":0,"listingDate":1634788800000,"exchange":"NASDAQ","adjPreClose":8.51,"preHourTrading":{"tag":"盘前","latestPrice":8.69,"preClose":8.51,"latestTime":"09:08 EST","volume":34,"amount":294.279962,"timestamp":1765375681613},"postHourTrading":{"tag":"盘后","latestPrice":8.3075,"preClose":8.69,"latestTime":"19:39 EST","volume":16903,"amount":146837.3929,"timestamp":1765413576046},"volumeRatio":0.35435,"impliedVol":1.0694,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/VTYX","defaultTab":"news","newsList":[{"id":"2588280059","title":"BRIEF-Ventyx Provides Clinical And Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2588280059","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588280059?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:23","pubTimestamp":1764685428,"startTime":"0","endTime":"0","summary":"BRIEF-Ventyx Provides Clinical And Corporate UpdatesDec 2 (Reuters) - Ventyx Biosciences Inc VTYX.O:VENTYX PROVIDES CLINICAL AND CORPORATE UPDATESVENTYX BIOSCIENCES INC: REVISING GUIDANCE FOR TOPLINE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1VGF2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2588055385","title":"Ventyx Biosciences Expands Phase 2 Recurrent Pericarditis Study Into Canada, EU, UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055385?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:13","pubTimestamp":1764681204,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences  said Tuesday it is expanding its phase 2 study of VTX2735 in patients with recurrent pericarditis into Canada, the EU and the UK.The expansion will allow Ventyx to introduce dose-ranging studies with the once-daily formulation of the current study, in preparation for a global phase 3 development plan, the company said.Ventyx said that interim analysis for the ongoing phase 2 study will be presented as part of its R&D day in Q1 of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","VTYX","BK4007"],"gpt_icon":0},{"id":"2588030914","title":"Ventyx Biosciences Inc: Revising Guidance for Topline Data Release From Interim Analysis of Phase 2 Rp Trial to Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030914?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:02","pubTimestamp":1764676920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1VGF2J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2588978030","title":"Ventyx Provides Clinical and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2588978030","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588978030?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:02","pubTimestamp":1764676920,"startTime":"0","endTime":"0","summary":"Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197764/0/en/Ventyx-Provides-Clinical-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2588777403","title":"Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777403","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:45","pubTimestamp":1764614700,"startTime":"0","endTime":"0","summary":"RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["NMRA","BK4007","VTYX"],"gpt_icon":0},{"id":"2588724064","title":"Ventyx Biosciences to Join Piper Sandler Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724064","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724064?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:02","pubTimestamp":1764590538,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025, from 4:00 to 4:25 PM ET. A live webcast of the event will be available on the Ventyx website, with a replay accessible for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ventyx Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7xc2rQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","PIPR","VTYX","BK4112","LU0314104364.USD","BK4007","LU2095319765.USD","LU2210150020.SGD","BK4127"],"gpt_icon":0},{"id":"2584929301","title":"Ventyx Biosciences Q3 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929301","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929301?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571483,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Ventyx Biosciences Q3 operating expenses USD 24.874 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:02:45.907 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbrcZxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2584640778","title":"Ventyx Biosciences to Join Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2584640778","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584640778?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:02","pubTimestamp":1763380928,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025. A webcast of the event will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ventyx Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL5mpDMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","VTYX","BK4007","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2581833070","title":"Ventyx Biosciences Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2581833070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581833070?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:55","pubTimestamp":1762541700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VTYX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 13:55 ET (18:55 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2581823258","title":"Promising Pipeline and Data Updates Justify Buy Rating for Ventyx Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2581823258","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581823258?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:26","pubTimestamp":1762529179,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on VTYX stock, giving a Buy rating today. Sam Slutsky has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-pipeline-and-data-updates-justify-buy-rating-for-ventyx-biosciences-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-pipeline-and-data-updates-justify-buy-rating-for-ventyx-biosciences-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTYX"],"gpt_icon":0},{"id":"1102468002","title":"Stock Track | Ventyx Biosciences (VTYX) Plummets 5.47% Pre-Market Despite Analyst Upgrades, Q3 Earnings May Disappoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1102468002","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102468002?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:43","pubTimestamp":1762526603,"startTime":"0","endTime":"0","summary":"Shares of Ventyx Biosciences, Inc. (VTYX) tumbled 5.47% in pre-market trading on Friday, despite several analysts raising their target prices for the stock. The sharp decline suggests that the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VTYX"],"gpt_icon":0},{"id":"2581074720","title":"Ventyx Biosciences price target raised to $16 from $14 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2581074720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581074720?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:11","pubTimestamp":1762517474,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Ventyx Biosciences (VTYX) to $16 from $14 and keeps a Buy rating on the shares. The firm said the targe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ventyx-biosciences-price-target-raised-to-16-from-14-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ventyx-biosciences-price-target-raised-to-16-from-14-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTYX"],"gpt_icon":0},{"id":"2581075097","title":"Ventyx Biosciences Inc : Canaccord Genuity Raises Target Price to $16 From $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2581075097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581075097?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:58","pubTimestamp":1762498688,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ093:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2581780530","title":"Ventyx Biosciences Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581780530","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581780530?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:00","pubTimestamp":1762495236,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences, Inc. ( ($VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ventyx-biosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ventyx-biosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2581045300","title":"Ventyx Biosciences Q3 EPS $(0.32) Beats $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045300","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045300?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:43","pubTimestamp":1762465427,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Q3 EPS $(0.32) Beats $(0.45) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48705543/ventyx-biosciences-q3-eps-0-32-beats-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ventyx Biosciences Q3 EPS $(0.32) Beats $(0.45) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2581043923","title":"Ventyx Biosciences Q3 net loss narrows to $22.8 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043923","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043923?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:33","pubTimestamp":1762464816,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Q3 net loss narrows to $22.8 mlnOverviewVentyx Q3 net loss narrows to $22.8 mln from $35.2 mln last yearCompany's cash reserves expected to fund operations into at least H2 2026VTX3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2581012742","title":"BRIEF-Ventyx Biosciences Q3 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012742","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012742?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462965,"startTime":"0","endTime":"0","summary":"BRIEF-Ventyx Biosciences Q3 EPS USD -0.32\n\n\nNov 06 (Reuters) - Ventyx Biosciences Q3 operating expenses USD 24.874 million.\n\nQ3 net income USD -22.829 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX477FBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2581012207","title":"Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012207?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462921,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA6ZL88W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2581705006","title":"Ventyx Biosciences Shares Rise After HC Wainwright Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2581705006","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581705006?lang=en_us&edition=fundamental","pubTime":"2025-11-06 03:53","pubTimestamp":1762372414,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences  shares were up over 10% in recent Wednesday trading after HC Wainwright upgraded the company's stock to buy from neutral, with a $18 price target.Trading volume stood at more than 2.6 million shares, compared with the daily average of over 3.7 million.Price: 8.92, Change: +0.82, Percent Change: +10.20","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VTYX"],"gpt_icon":0},{"id":"2581878727","title":"HC Wainwright Upgrades Ventyx Biosciences to Buy From Neutral, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2581878727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581878727?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:52","pubTimestamp":1762347131,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences (VTYX) has an average rating of Buy and mean price target of $12.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VTYX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.ventyxbio.com","stockEarnings":[{"period":"1week","weight":0.0718},{"period":"1month","weight":-0.0296},{"period":"3month","weight":2.5907},{"period":"6month","weight":2.4177},{"period":"1year","weight":1.8272},{"period":"ytd","weight":2.8858}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.032083},{"month":2,"riseRate":0.5,"avgChangeRate":0.472556},{"month":3,"riseRate":0.25,"avgChangeRate":-0.139982},{"month":4,"riseRate":0.75,"avgChangeRate":0.007413},{"month":5,"riseRate":0.75,"avgChangeRate":0.169529},{"month":6,"riseRate":0.25,"avgChangeRate":-0.151975},{"month":7,"riseRate":1,"avgChangeRate":0.16945},{"month":8,"riseRate":0.25,"avgChangeRate":0.018158},{"month":9,"riseRate":0.75,"avgChangeRate":0.25535},{"month":10,"riseRate":0.25,"avgChangeRate":0.269009},{"month":11,"riseRate":0.4,"avgChangeRate":-0.114905},{"month":12,"riseRate":0.6,"avgChangeRate":-0.00931}],"exchange":"NASDAQ","name":"Ventyx Biosciences, Inc.","nameEN":"Ventyx Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ventyx Biosciences, Inc.(VTYX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ventyx Biosciences, Inc.,VTYX,Ventyx Biosciences, Inc.股票,Ventyx Biosciences, Inc.股票老虎,Ventyx Biosciences, Inc.股票老虎国际,Ventyx Biosciences, Inc.行情,Ventyx Biosciences, Inc.股票行情,Ventyx Biosciences, Inc.股价,Ventyx Biosciences, Inc.股市,Ventyx Biosciences, Inc.股票价格,Ventyx Biosciences, Inc.股票交易,Ventyx Biosciences, Inc.股票购买,Ventyx Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ventyx Biosciences, Inc.(VTYX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}